Table 3. Comparison of clinical characteristics between patients with acquired T790M and those without T790M.
| All patients | Acquired T790M (+) | Acquired T790M (−) | p value | |||
|---|---|---|---|---|---|---|
| Total No. | 42 | 20 (47.6%) | 22 (52.4%) | |||
| Age, median years | 57.5 | 58.2 | 54.5 | 0.314a | ||
| (range) | (35.2–81.1) | (35.9–81.1) | (35.2–78.8) | |||
| Sex | 0.952 | |||||
| Female | 25 | 12 | (48.0%) | 13 | (52.0%) | |
| Male | 17 | 8 | (47.1%) | 9 | (52.9%) | |
| Smoking | 0.714* | |||||
| Never-smokers | 33 | 15 | (45.5%) | 18 | (54.5%) | |
| Smokers | 9 | 5 | (55.6%) | 4 | (44.4%) | |
| Pre-afatinib | 0.827 | |||||
| TKI-naïve | 14 | 7 | (50.0%) | 7 | (50.0%) | |
| Prior TKI exposure | 28 | 13 | (46.4%) | 15 | (53.6%) | |
| EGFR mutation | 0.142 | |||||
| Del-19 | 14 | 9 | (64.3%) | 5 | (35.7%) | |
| L858R | 22 | 10 | (45.5%) | 12 | (54.5%) | |
| Others | 6 | 1# | (16.7%) | 5 | (83.3%) | |
| Afatinib response | 0.175* | |||||
| PR | 37 | 16 | (43.2%) | 21 | (56.8%) | |
| SD | 5 | 4 | (80/0%) | 1 | (20.0%) | |
#
L861Q + T790M.
*
By Fisher exact test.
a
By Mann-Whitney U test.
EGFR: epidermal growth factor receptor, Del-19: deletion in exon 19, TKI: tyrosine kinase inhibitor, PR: partial response, SD: stable disease.